Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amicus (FOLD), AstraZeneca (AZN) and Compugen (CGEN).
Amicus (FOLD)
Leerink Partners analyst Joseph Schwartz maintained a Hold rating on Amicus on June 8. The company’s shares closed last Wednesday at $10.58, close to its 52-week low of $8.68.
According to TipRanks.com, Schwartz is a 4-star analyst with an average return of 13.4% and a 47.6% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Crinetics Pharmaceuticals, and Mereo Biopharma Group Plc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amicus with a $15.67 average price target, which is a 50.7% upside from current levels. In a report issued on May 27, Needham also initiated coverage with a Hold rating on the stock.
See today’s analyst top recommended stocks >>
AstraZeneca (AZN)
Leerink Partners analyst Andrew Berens maintained a Buy rating on AstraZeneca on June 8. The company’s shares closed last Wednesday at $57.60.
According to TipRanks.com, Berens is a 4-star analyst with an average return of 9.1% and a 60.5% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AstraZeneca with a $66.00 average price target.
Compugen (CGEN)
In a report issued on June 8, Daina Graybosch from Leerink Partners maintained a Buy rating on Compugen, with a price target of $16.00. The company’s shares closed last Wednesday at $7.82, close to its 52-week low of $6.74.
According to TipRanks.com, Graybosch is a 3-star analyst with an average return of 10.2% and a 41.2% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Werewolf Therapeutics, Inc., Silverback Therapeutics, and Molecular Partners AG.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Compugen with a $17.50 average price target, representing a 128.5% upside. In a report issued on June 8, Oppenheimer also assigned a Buy rating to the stock with a $19.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
